Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
PAVMED INC (PAVM)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$1.66-8.79%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PAVM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain capital discipline and manage cash burn | It aims to control cash burn and extend its cash runway. | Broken | operating losses worsen beyond -$8.0M per quarter | Operating income: $-7.022M FY2026-Q2; GAAP. Published target: reduce quarterly operating losses below -$4.7M. Target period is not explicitly aligned with this observation. Aug 13, 2026-7,022,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making medical-device development and commercialization story, with potential tied to products still being advanced. The thesis is on watch: management is progressing on EsoGuard coverage and revenue, but recent financial performance is weak and cash continues to decline.
The valuation model indicates PAVM is expensive versus peers, with a large premium and an expectations gap linked to optionality, meaning value investors assign to possible future outcomes. Model confidence is low, and the evidence does not show that the premium is supported by current earnings; the fragility assessment is low because it does not identify a broader combination of expensive valuation, weak results, and turbulent conditions.
Near term, weak results and erratic earnings make the next report uncertain, while operating cash flow remains negative and cash declined from the first to the second quarter of 2026. Over the multi-year view, EsoGuard revenue rose modestly and gained its first laboratory benefit manager coverage policy, while Veris and PortIO development and related spending continue. Capital management remains a concern, and the evidence on management execution is mixed overall.
The central swing factor is whether EsoGuard can build commercial momentum and secure broader reimbursement while the company manages its cash burn. Near term, weaker employment data could weigh on cyclical healthcare names, while continued earnings strength from sector leaders such as ABT, MDT, and SYK could support sector momentum; misses or lower guidance could remove that tailwind.
For the next 1 to 3 years, PAVM remains a speculative, loss-making thesis with early commercial and reimbursement progress, but substantial execution and cash-management risks. The key test is whether commercial progress becomes durable while clinical development advances without worsening financial strain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “GAAP net loss attributable to common stockholders was approximately $5.5 million, or $(0.87) per common share on a diluted basis.” “GAAP net loss attributable to common stockholders was approximately $7.0 million, or $(4.42) per common share on a diluted basis.”
Advance clinical development of medical device products | PAVmed is working to advance its medical device trials. | Intact | clinical trial progress stalls or regresses over next year | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “|| ○ | Continued development of the implantable physiological monitor toward an early 2027 FDA 510(k) submission, with design freeze nearing completion and manufacturing test runs performing well in preliminary verification and validation ahead of final clinical testing.” “● Veris continued development of its implantable physiological monitor, with presubmission and testing activities expected to begin soon in support of a planned FDA 510(k) submission.” Delivery assessment Nov 4, 2026 |
Increase revenue from medical device sales | PAVmed is working to advance its medical device trials. | Intact | revenue growth falls below consensus estimates next year | Revenue: $33,000 FY2026-Q2; GAAP. Published target: grow revenue from $340K in 2026 to $652.5K in 2027. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 202633,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “|| ○ | Continued development of the implantable physiological monitor toward an early 2027 FDA 510(k) submission, with design freeze nearing completion and manufacturing test runs performing well in preliminary verification and validation ahead of final clinical testing.” “● Veris continued development of its implantable physiological monitor, with presubmission and testing activities expected to begin soon in support of a planned FDA 510(k) submission.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.28 → $-1.98 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.28 | $652,500 | 1 / 1 |
| 2026-07-25 | $-1.28 | $652,500 | 1 / 1 |
| 2026-07-26 | $-1.28 | $652,500 | 1 / 1 |
| 2026-07-27 | $-1.28 | $652,500 | 1 / 1 |
| 2026-07-28 | $-1.28 | $652,500 | 1 / 1 |
| 2026-07-29 | $-1.28 | $652,500 | 1 / 1 |
| 2026-07-30 | $-2.45 | $652,500 | 1 / 2 |
| 2026-07-31 | $-2.45 | $652,500 | 1 / 2 |
| 2026-08-01 | $-1.28 | $652,500 | 1 / 1 |
| 2026-08-02 | $-1.28 | $652,500 | 1 / 1 |
| 2026-08-03 | $-1.28 | $652,500 | 1 / 1 |
| 2026-08-04 | $-1.28 | $652,500 | 1 / 1 |
| 2026-08-05 | $-2.45 | $652,500 | 1 / 2 |
| 2026-08-06 | $-2.45 | $652,500 | 1 / 2 |
| 2026-08-07 | $-1.28 | $652,500 | 1 / 1 |
| 2026-08-08 | $-2.45 | $652,500 | 1 / 2 |
| 2026-08-09 | $-2.45 | $652,500 | 1 / 2 |
| 2026-08-10 | $-2.45 | $652,500 | 1 / 2 |
| 2026-08-12 | $-1.28 | $652,500 | 1 / 1 |
| 2026-08-13 | $-1.28 | $652,500 | 1 / 1 |
| 2026-08-14 | $-1.28 | $652,500 | 1 / 1 |
| 2026-08-15 | $-1.28 | $652,500 | 1 / 1 |
| 2026-08-16 | $-1.28 | $652,500 | 1 / 1 |
| 2026-08-17 | $-1.28 | $652,500 | 1 / 1 |
| 2026-08-18 | $-1.28 | $652,500 | 1 / 1 |
| 2026-08-19 | $-1.28 | $652,500 | 1 / 1 |
| 2026-08-20 | $-1.98 | $600,000 | 1 / 1 |
| 2026-08-21 | $-1.98 | $600,000 | 1 / 1 |
| 2026-08-22 | $-1.98 | $600,000 | 1 / 1 |
| 2026-08-23 | $-1.98 | $600,000 | 1 / 1 |
| 2026-08-24 | $-1.98 | $600,000 | 1 / 1 |
| 2026-08-25 | $-1.98 | $600,000 | 1 / 1 |
| 2026-08-26 | $-1.98 | $600,000 | 1 / 1 |
| 2026-08-27 | $-1.98 | $600,000 | 1 / 1 |
| 2026-08-28 | $-1.98 | $600,000 | 1 / 1 |
| 2026-08-29 | $-1.98 | $600,000 | 1 / 1 |
| 2026-08-30 | $-1.98 | $600,000 | 1 / 1 |
| 2026-08-31 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-01 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-02 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-03 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-04 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-05 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-06 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-07 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-08 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-09 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-10 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-11 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-12 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-13 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-14 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-15 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-16 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-17 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-18 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-19 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-20 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-21 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-22 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-23 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-24 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-25 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-26 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-27 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-28 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-29 | $-1.98 | $600,000 | 1 / 1 |
| 2026-09-30 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-01 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-02 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-03 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-04 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-05 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-06 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-07 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-08 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-09 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-10 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-11 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-12 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-13 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-14 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-15 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-16 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-17 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-18 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-19 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-20 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-21 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-22 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-23 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-24 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-25 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-26 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-27 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-28 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-29 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-30 | $-1.98 | $600,000 | 1 / 1 |
| 2026-10-31 | $-1.98 | $600,000 | 1 / 1 |
| 2026-11-01 | $-1.98 | $600,000 | 1 / 1 |
| 2026-11-02 | $-1.98 | $600,000 | 1 / 1 |
| 2026-11-03 | $-1.98 | $600,000 | 1 / 1 |
| 2026-11-04 | $-1.98 | $600,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.